liver-2018-keynote

2 / 9

Page 10
Notes:
alliedacademies
Journal of Gastroenterology and Digestive Diseases | Volume 3
May 25-26, 2018 | New York, USA
World Liver Conference 2018
Chronic infection with hepatitis B virus (HBV) is associated
with the development of progression of chronic liver
disease (CLD) and the appearance of hepatocellular carcinoma
(HCC). HCC is a prevalent cancer worldwide with few treatment
options. Given that HCCdevelopsmost oftenon the background
of chronic inflammation, experiments were designed to test
the hypothesis that selected probiotic bacteria that suppress
inflammation could be used as a simple and inexpensive
means to prevent or delay the appearance of HCC. To test this,
hepatitis B x (HBx) transgenic mice, which develop progressive
liver lesions that culminate in HCC, were treated with a mixture
of probiotic bacteria (Synbiotic 2000) several months prior to
the development of dysplasia and HCC. The results showed a
significant reduction in the number and size of dysplastic and
HCC nodules compared to control transgenic mice. Microarray
analysis of selected immune and cancer associated markers
showed a strong reduced expression in the liver of mice treated
with Synbiotic 2000 compared to controls. Thus, Synbiotic
2000 attenuates the pathogenesis of HCC, and may be useful in
cancer chemoprevention, not only for HCC, but perhaps against
other cancers that often develop on the background of chronic
inflammation.
Speaker Biography
Mark A Feitelson received his PhD in Microbiology and Immunology in 1979 from the
UCLA School of Medicine. He was an American Cancer Society Post-doctoral fellow at
Stanford University from 1980-82, and was then recruited to the Fox Chase Cancer
Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, he became an Associate
Professor of Pathology and Cell Biology and Head of the Molecular Diagnostics Lab in
Microbiology at Thomas Jefferson University. In 2007, he moved to Temple University,
where he is now Professor of Biology. His research has been supported by NIH,
industry and foundations for more than 35 years; he has more than 140 publications,
and is currently Head of the Professional Science Master’s program in Biotechnology
at Temple University. Since 1980, his research interests have encompassed the
pathogenesis of chronic hepatitis B infection and development of hepatocellular
carcinoma on the cell and molecular levels.
e:
Mark A Feitelson
Temple University, USA
Symbiotic bacteria provide chemoprevention against hepatitis B virus mediated
hepatocellular carcinoma in hepatitis B x transgenic mice